Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Senti Biosciences Holdings, Inc. - Common Stock
(NQ:
SNTI
)
0.1779
-0.0101 (-5.37%)
Delayed Quote
Updated: 4:00 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Senti Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
Next >
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
July 22, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
June 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
June 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
May 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
May 22, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
May 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm
May 15, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
May 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI
May 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
April 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Senti Bio Announces Reverse Stock Split
July 16, 2024
Shares expected to begin trading on split-adjusted basis on July 18, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
July 02, 2024
Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices.
Via
MarketBeat
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
July 01, 2024
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 09, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
April 30, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
March 21, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
January 05, 2024
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
December 22, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
November 13, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
November 06, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
October 31, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
September 27, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio to Participate in Upcoming Conferences
September 26, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio to Participate in Upcoming Investor Conferences
September 05, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
August 11, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
August 10, 2023
From
Senti Biosciences, Inc.
Via
GlobeNewswire
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 20, 2023
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages
From
Senti Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
